Join our daily newsletter At The Bell to receive exclusive market insights
- Bio-Gene Technology (BGT) signs a research agreement with the University of Florida, advancing its program to phase two
- The company has previously engaged with researchers at the University to test Qcide and Flavocide against resistant strains of flying insects
- Phase two will explore synergetic traits which may be evident in combination treatments of Qcide or Flavocide with other compounds
- The studies are set to commence early next year with reporting planned for early in the second quarter of 2022
- Bio-Gene Technology shares are trading 2.56 per cent higher at 20 cents
Bio-Gene Technology (BGT) has signed a research agreement with the University of Florida, advancing its program to phase two.
The company has previously engaged with researchers at the university to test Qcide and Flavocide against resistant strains of flying insects.
Phase one testing confirmed this strain resistance, demonstrating a close alignment with their dose response curves between both resistant and susceptible strains.
Phase two will explore synergetic traits which may be evident in combination treatments of Qcide or Flavocide with other compounds.
The studies are set to commence early next year with reporting planned for early in the second quarter of 2022.
Bio-Gene’s CEO and managing director, Richard Jagger, said BGT’s corporate objectives have been strengthened by recent commercial agreements.
“This has been exemplified in our announcement today to proceed to phase two of the research program with the University of Florida. This is consistent with our overall strategy to undertake targeted research to promote uses for Qcide and Flavocide and support intellectual property rights to our technology.”
Bio-Gene Technology shares were up 2.56 per cent to trade at 20 cents at 2:39 pm AEDT.
